Sunao Manabe

Sunao Manabe serves as President and CEO of Daiichi Sankyo, a Japanese pharmaceutical company that has undergone a dramatic strategic transformation from a diversified pharma company into a focused oncology powerhouse. The pivot centers on Daiichi Sankyo's proprietary DXd antibody-drug conjugate (ADC) technology platform, which attaches potent chemotherapy payloads to targeting antibodies that deliver the drug directly to cancer cells. The flagship product Enhertu (trastuzumab deruxtecan), developed in partnership with AstraZeneca under a deal worth up to $69 billion in milestone payments, has shown unprecedented efficacy across multiple HER2-expressing cancers — breast, lung, gastric, and colorectal. Clinical trial results have repeatedly exceeded expectations, expanding Enhertu's addressable patient population far beyond initial projections. Daiichi Sankyo's ADC pipeline extends beyond Enhertu to include datopotamab deruxtecan (Dato-DXd, targeting TROP2 cancers) and several earlier-stage ADC candidates. The company's DXd linker-payload technology is considered best-in-class, giving Daiichi Sankyo a sustainable competitive advantage in the rapidly growing ADC market. Key stock drivers include Enhertu sales trajectory and label expansions, Dato-DXd clinical trial results and approvals, ADC pipeline progression, AstraZeneca partnership milestones, competition from other ADC developers, and the sustainability of Japan's premium valuation for the stock.